HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>Takeda’s sales team is fully prepared for the launch of fruquintinib in EU. 2024 full-year overseas sales may once again beat the expectations. High growth is expected from 2024 to 2026.</li>
<li>Peak sales of fruquintinib + savolitinib + surufatinib that recorded in HUTCHMED’s revenue is expected to be over US$750 million.Without considering other revenue, market value would reach about US$4.5 billion.</li>
<li>HUTCHMED’s pipeline lacks blockbuster products and the indications are small. With the rise of PROTAC, small molecule drugs would face challenges, which would test the management's resilience in the future.</li>
</ul>


Takeda’s sales team is fully prepared for the launch of fruquintinib in EU. 2024 full-year overseas sales may once again beat the expectations. High growth is expected from 2024 to 2026.
Peak sales of fruquintinib + savolitinib + surufatinib that recorded in HUTCHMED’s revenue is expected to be over US$750 million.Without considering other revenue, market value would reach about US$4.5 billion.
HUTCHMED’s pipeline lacks blockbuster products and the indications are small. With the rise of PROTAC, small molecule drugs would face challenges, which would test the management's resilience in the future.


Hutchmed China Ltd (13.HK/​​HCM.US) - Time to Reassess Valuation Prospects Despite the Pain Points

Blue Lotus China New Economy Research, Blue Lotus Research Institute

Eric Wen

Blue Lotus China New Economy Research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>981HK: Huawei Wuhu Supercomputing Center opens services, which benefits SMIC. (/)</li>
<li>LKNCY US: Cotti Coffee Changes Product Formulas and Supply Chain, Ramps up Promotion for Fruit Coffee (-)</li>
<li>BGNE US: AstraZeneca Calquence Phase III results set up competition for BeiGene's Zanubrutinib</li>
</ul>


981HK: Huawei Wuhu Supercomputing Center opens services, which benefits SMIC. (/)
LKNCY US: Cotti Coffee Changes Product Formulas and Supply Chain, Ramps up Promotion for Fruit Coffee (-)
BGNE US: AstraZeneca Calquence Phase III results set up competition for BeiGene's Zanubrutinib


[Blue Lotus Daily]:981HK/LKNCY US/BGNE US

Pan-Asia Index Flows & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Pan-Asia Index Flows & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

New Oriental Education & Techn / Event-Driven

<ul>
<li>The HSCEI serves as a benchmark to reflect the overall performance of the top 50 "Mainland China" securities listed in Hong Kong.</li>
<li>In this insight, we take a look at the potential index changes and the resultant capping flows for HSCEI index rebal event in September 2024.</li>
<li>Based on the current data, I see two ADDs and two DELs.</li>
</ul>


The HSCEI serves as a benchmark to reflect the overall performance of the top 50 "Mainland China" securities listed in Hong Kong.
In this insight, we take a look at the potential index changes and the resultant capping flows for HSCEI index rebal event in September 2024.
Based on the current data, I see two ADDs and two DELs.


Quiddity Leaderboard HSCEI Sep 24: Two Changes Possible; US$256mn One-Way

Andy Fu

<ul>
<li>As Chinese population ages, healthcare is a major source of consumption. Yet we are the most pessimistic for it to become a pillar of consumption;</li>
<li>Low healthcare spending in China is achieved by underpaying doctors and nurses. Enhancing life quality, instead of only curing disease, can meaningfully improve consumption; </li>
<li>However, consumer healthcare begets a larger and more common economic phenomenon, which is underpricing. The issue of underpricing stems from low compliance cost, in our opinion.</li>
</ul>


As Chinese population ages, healthcare is a major source of consumption. Yet we are the most pessimistic for it to become a pillar of consumption;
Low healthcare spending in China is achieved by underpaying doctors and nurses. Enhancing life quality, instead of only curing disease, can meaningfully improve consumption; 
However, consumer healthcare begets a larger and more common economic phenomenon, which is underpricing. The issue of underpricing stems from low compliance cost, in our opinion.


How to Stimulate China's Consumption, Part III

<ul>
<li>The growth of TIDES business slowed down, and revenue decreased QoQ despite increasing production capacity.As the main growth point of WuXi AppTec’s future performance, this is not a good signal.</li>
<li>Due to BIOSECURE Act, US companies have been negotiating with other contract manufacturers so as to reduce reliance on WuXi AppTec.Let’s see the situation of new orders in following quarters.</li>
<li>WuXi AppTec’s performance recovery is closely related to the pace of Fed's interest rate cuts. From the perspective of growth outlook/macro environment/geopolitical conflicts, WuXi AppTec is still in "dangerous period".</li>
</ul>


The growth of TIDES business slowed down, and revenue decreased QoQ despite increasing production capacity.As the main growth point of WuXi AppTec’s future performance, this is not a good signal.
Due to BIOSECURE Act, US companies have been negotiating with other contract manufacturers so as to reduce reliance on WuXi AppTec.Let’s see the situation of new orders in following quarters.
WuXi AppTec’s performance recovery is closely related to the pace of Fed's interest rate cuts. From the perspective of growth outlook/macro environment/geopolitical conflicts, WuXi AppTec is still in "dangerous period".


WuXi AppTec (2359.HK/603259.CH) - The Pain of 2024 Has Just Begun

China

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeiGene (BGNE US)

Hutchmed China Ltd (13.HK/HCM.US) - Time to Reassess Valuation Prospects Despite the Pain Points

HUTCHMED’s 2024 full-year sales may once again exceed expectations. It's time to recalculate the peak sales of pipeline and the Company’s outlook....

Xinyao (Criss) Wang

[Blue Lotus Daily]:981HK/LKNCY US/BGNE US

Huawei's new supercomputing center benefits SMIC; Cotti Coffee changes formulas; AstraZeneca's results pose competition for BeiGene.

Blue Lotus Research Institute

Quiddity Leaderboard HSCEI Sep 24: Two Changes Possible; US$256mn One-Way

JD Logistics and SenseTime are currently ranked 65th and 64th respectively and we see them as expected DELs. We see PICC Property & Casualty and...

Janaghan Jeyakumar, CFA

How to Stimulate China's Consumption, Part III

China's healthcare system is supply efficient, which leads to underpaying the healthcare professionals' service but overmedicates. To change,...

Blue Lotus Research Institute

WuXi AppTec (2359.HK/603259.CH) - The Pain of 2024 Has Just Begun

HR8333 proposal involving WuXi AppTec/WuXi Bio faced obstacles when included in NDAA.After the presidential election, new legislation process is...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hutchmed China Ltd (13.HK/​​HCM.US) - Time to Reassess Valuation Prospects Despite the Pain Points

HUTCHMED’s 2024 full-year sales may once again exceed expectations. It's time to recalculate the peak sales of pipeline and the Company’s outlook....

Xinyao (Criss) Wang

[Blue Lotus Daily]:981HK/LKNCY US/BGNE US

​Huawei's new supercomputing center benefits SMIC; Cotti Coffee changes formulas; AstraZeneca's results pose competition for BeiGene.

Blue Lotus Research Institute

Quiddity Leaderboard HSCEI Sep 24: Two Changes Possible; US$256mn One-Way

JD Logistics and SenseTime are currently ranked 65th and 64th respectively and we see them as expected DELs. We see PICC Property & Casualty and...

Janaghan Jeyakumar, CFA

How to Stimulate China's Consumption, Part III

China's healthcare system is supply efficient, which leads to underpaying the healthcare professionals' service but overmedicates. To change,...

Blue Lotus Research Institute

WuXi AppTec (2359.HK/603259.CH) - The Pain of 2024 Has Just Begun

HR8333 proposal involving WuXi AppTec/WuXi Bio faced obstacles when included in NDAA.After the presidential election, new legislation process is...

Xinyao (Criss) Wang

Hutchmed China Ltd (13.HK/HCM.US) - Time to Reassess Valuation Prospects Despite the Pain Points

Huawei's new supercomputing center benefits SMIC; Cotti Coffee changes formulas; AstraZeneca's results pose competition for BeiGene.